2,5-Dimethyl-4,5,6,7-tetrahydro-1,3-benzothiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2,5-Dimethyl-4,5,6,7-tetrahydro-1,3-benzothiazole
• 英文别名: 2,5-dimethyl-4,5,6,7-tetrahydro-1,3-benzothiazole
• 化学式: C₉H₁₃NS
• 分子量: 167.27
• InChiKey: MYODCLXJQDIBMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• BICYCLIC COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20140243310A1

  公开（公告）日：2014-08-28

  The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种由以下公式（I）表示的化合物：其中每个符号如规范中定义的，或其盐。
• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：Chen Wei

  公开号：US20160031891A1

  公开（公告）日：2016-02-04

  Disclosed herein are amido compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文公开了一种与布鲁顿酪氨酸激酶（Btk）形成共价键的酰胺化合物。还描述了Btk的不可逆抑制剂。还公开了包括这些化合物的药物组合物。公开了使用Btk抑制剂的方法，单独或与其他治疗剂一起用于治疗自身免疫性疾病或病况，异体免疫性疾病或病况，癌症，包括淋巴瘤和炎症性疾病或病况。
• [EN] ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF<br/>[FR] COMPOSÉ CONTRE LE VIRUS DE LA GRIPPE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 抗流感病毒化合物及其制备方法和用途
  申请人：SICHUAN HAISCO PHARMACEUTICAL CO LTD

  公开号：WO2021032209A1

  公开（公告）日：2021-02-25

  涉及作为Hemagglutinin抑制剂的式(I-a)化合物、其异构体或其药学上可接受的盐，及其制备方法。所述化合物用于制备治疗与Hemagglutinin相关的疾病的药物。
• US9133129B2
  申请人：——

  公开号：US9133129B2

  公开（公告）日：2015-09-15
• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：PHARMACYCLICS LLC

  公开号：WO2016019233A1

  公开（公告）日：2016-02-04

  Disclosed herein are amido compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.